Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.0
3.8
Journals
Bioengineering
Special Issues
Bioengineering Approaches for the Treatment of Cancer
share announcement

Bioengineering Approaches for the Treatment of Cancer

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Biomedical Engineering and Biomaterials".

Deadline for manuscript submissions: closed (15 July 2023) | Viewed by 4567

Special Issue Editors

Dr. Vaibhav Jain

E-Mail Website
Guest Editor
Abramson Cancer Center, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Interests: Cancer Biology; Lipid metabolism; Autophagy; Inflammation; Polyamine metabolism; Therapy resistance
Special Issues, Collections and Topics in MDPI journals
Dr. Vito W. Rebecca

E-Mail Website
Guest Editor
Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
Interests: Cancer Biology; Cell Biology; Cellular Stress and Cell Signaling; Developmental and Stem Cell Biology; Translational Research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biomedical engineering (BME) and molecular engineering (ME) are umbrella terms, which include but are not limited to the application of engineering principles to improve or solve problems in medicine and biology. Various new methods and tools have been developed in recent years that can be utilized directly or can be applied to existing treatment options for multiple diseases including cancer. While BME applies engineering principles utilizing physical tools for different applications including improved anticancer drug delivery to achieve a high concentration of anticancer agents directly to the tumor and to maximize the uptake of anticancer agents by cancer cells with minimum effect on bystander cells (e.g., using nanoparticles, hydrogels, micelles, and liposomes, etc.), and modeling the tumor microenvironment (3D models of cancer), ME is more closely related to engineering biomolecules to solve such problems. Some successful examples of ME for cancer involve engineering biomolecules such as DNA (gene therapy, CRISPR, etc.), RNA (microRNAs, aptamers, etc.), peptides and protein-peptide vaccines, antibody, antibody–drug conjugates, enzymes, T cell receptors for chimeric antigen receptor (CAR)-T cell therapy, etc.). This Special Issue will cover various bioengineering approaches which are being utilized to treat different types of cancer.

Dr. Vaibhav Jain
Dr. Vito W. Rebecca
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer targeting bioengineering approaches
  • drug delivery
  • gene therapy
  • protein engineering
  • DNA engineering
  • RNA engineering
  • peptide engineering
  • nanoparticles
  • 3D tumor models

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

15 pages, 3335 KiB  
Article
Spatial Alignment of Organoids Tracking Subclonal Chemotherapy Resistance in Pancreatic and Ampullary Cancer
by Md Shahadat Hossan, Ethan Samuel Lin, Eleanor Riedl, Austin Stram, Eric Mehlhaff, Luke Koeppel, Jamie Warner, Inem Uko, Lori Mankowski Gettle, Sam Lubner, Stephanie M. McGregor, Wei Zhang, William Murphy and Jeremy D. Kratz
Bioengineering 2023, 10(1), 91; https://doi.org/10.3390/bioengineering10010091 - 10 Jan 2023
Cited by 1 | Viewed by 2577
Abstract
Pancreatic and ampullary cancers remain highly morbid diseases for which accurate clinical predictions are needed for precise therapeutic predictions. Patient-derived cancer organoids have been widely adopted; however, prior work has focused on well-level therapeutic sensitivity. To characterize individual oligoclonal units of therapeutic response, [...] Read more.
Pancreatic and ampullary cancers remain highly morbid diseases for which accurate clinical predictions are needed for precise therapeutic predictions. Patient-derived cancer organoids have been widely adopted; however, prior work has focused on well-level therapeutic sensitivity. To characterize individual oligoclonal units of therapeutic response, we introduce a low-volume screening assay, including an automated alignment algorithm. The oligoclonal growth response was compared against validated markers of response, including well-level viability and markers of single-cell viability. Line-specific sensitivities were compared with clinical outcomes. Automated alignment algorithms were generated to match organoids across time using coordinates across a single projection of Z-stacked images. After screening for baseline size (50 μm) and circularity (>0.4), the match efficiency was found to be optimized by accepting the diffusion thresholded with the root mean standard deviation of 75 μm. Validated well-level viability showed a limited correlation with the mean organoid size (R = 0.408), and a normalized growth assayed by normalized changes in area (R = 0.474) and area (R = 0.486). Subclonal populations were defined by both residual growth and the failure to induce apoptosis and necrosis. For a culture with clinical resistance to gemcitabine and nab-paclitaxel, while a therapeutic challenge induced a robust effect in inhibiting cell growth (GΔ = 1.53), residual oligoclonal populations were able to limit the effect on the ability to induce apoptosis (GΔ = 0.52) and cell necrosis (GΔ = 1.07). Bioengineered approaches are feasible to capture oligoclonal heterogeneity in organotypic cultures, integrating ongoing efforts for utilizing organoids across cancer types as integral biomarkers and in novel therapeutic development. Full article
(This article belongs to the Special Issue Bioengineering Approaches for the Treatment of Cancer)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research

7 pages, 1240 KiB  
Brief Report
FD-2, an Anticervical Stenosis Device for Patients Undergoing Radical Trachelectomy or Cervical Conization
by Seiji Mabuchi, Shoji Kamiura, Takuya Saito, Hayato Furukawa, Azusa Abe and Takashi Sasagawa
Bioengineering 2023, 10(9), 1032; https://doi.org/10.3390/bioengineering10091032 - 1 Sep 2023
Viewed by 1267
Abstract
This study aimed to introduce FD-2, a newly developed anticervical stenosis device for patients with cervical cancer undergoing radical trachelectomy. Using ethylene-vinyl acetate copolymers, we developed FD-2 to prevent uterine cervical stenosis after radical trachelectomy. The tensile test and extractables and leachables testing [...] Read more.
This study aimed to introduce FD-2, a newly developed anticervical stenosis device for patients with cervical cancer undergoing radical trachelectomy. Using ethylene-vinyl acetate copolymers, we developed FD-2 to prevent uterine cervical stenosis after radical trachelectomy. The tensile test and extractables and leachables testing were performed to evaluate FD-2’s safety as a medical device. FD-2 was indwelled in three patients with cervical cancer during radical trachelectomy and its utility was preliminarily evaluated. FD-2 consists of a head (fish-born-like structure), neck (connecting bridges), and body (tubular structure); the head is identical to FD-1, an intrauterine contraceptive device. FD-2 passed the tensile test and extractables and leachables testing. The average time required for the application or removal of FD-2 in cervical cancer patients was less than 10 s. The median duration of FD-2 indwelling was 8 weeks. No complications, including abdominal pain, pelvic infections, or hemorrhages, associated with FD-2 indwelling were reported. At the 3–12-month follow-up after the radical trachelectomy, no patients developed cervical stenosis or experienced dysmenorrhea. In conclusion, we developed FD-2, a novel device that can be used for preventing cervical stenosis after radical trachelectomy for uterine cervical cancer. Full article
(This article belongs to the Special Issue Bioengineering Approaches for the Treatment of Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop